Pharmaceutical Adium agrees with Moderna to distribute vaccines in America

The pharmaceutical company Adium Pharma, based in Montevideo (Uruguay) and with four production plants in the region, has agreed with Moderna to collaborate in the distribution and marketing of the Spikevax vaccine against COVID-19 in Latin America.

“As part of the agreement reached, Adium will collaborate with Moderna in the management of supply contracts already in force with governments, as well as in continuing medical education and the generation of new agreements in countries where Spikevax is not yet present”, indicates a statement issued by the company.

The text also includes statements from the chief executive of Adium Pharma, Patricio Rodríguez, who assured that they are “delighted” to have partnered with Moderna, a company that he defined as “a leader in the fight against the pandemic.”

“We are eager to collaborate with the goal of expanding vaccination rates in Latin America, helping patients, doctors and governments in this effort. This alliance confirms our purpose of supplying all of Latin America with innovative treatments that help improve their quality of life.”, he stressed.

Adium Pharma has a presence in Argentina, Bolivia, Brazil, Central America, Chile, Colombia, Ecuador, Mexico, Paraguay, Peru and Uruguay.

For his part, Stéphane Bancel, CEO of Moderna, said that the “Collaboration with Adium will help ensure broader access and distribution of Moderna’s COVID-19 vaccine throughout Latin America.”

Bancel also stated that Moderna’s expansion throughout the world will allow the pharmaceutical company to “provide health security against COVID-19 and future diseases that can be prevented with a vaccine.”

The Modern biotechnology company, with a commercial presence in eleven countries (Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, Switzerland, the United Kingdom and the United States), announced in June 2020 that a month later it would start the third, and final, phase of its vaccine against the SARS-CoV-2 coronavirus.

In November of that year, the company reported in a statement that it was 94.5% effective and that it met the efficacy criteria required for marketing.

Moderna’s COVID-19 vaccine has been approved in more than 70 countries, and in 2021 some 807 million doses were distributed worldwide, of which only 25% went to low-income countries and averages, according to company figures.